-
Archit Organosys receives USFDA approval for generic eye care drug
Archit Organosys has received approval from the United States Food and Drug Administration (USFDA) for its generic eye care drug, Olopatadine Hydrochloride Ophthalmic Solution.
-
Archit Organosys signs licensing agreement with Novartis for generic eye care drug
Archit Organosys has signed a licensing agreement with Novartis for the exclusive rights to market and distribute a generic version of Novartis's eye care drug, Xalatan.
-
Archit Organosys launches new eye care manufacturing facility in India
Archit Organosys has launched a new eye care manufacturing facility in India. The facility will produce a range of eye care products, including eye drops, ointments, and gels.
-
Archit Organosys receives USFDA approval for its Abbreviated New Drug Application (ANDA) for Rivastigmine Tartrate Capsules
Archit Organosys Limited, a leading Indian pharmaceutical company, today announced that it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rivastigmine Tartrate Capsules in the strengths of 1.5 mg, 3 mg, 4.5 mg and 6 mg.
-
Archit Organosys launches new range of generic drugs in India
Archit Organosys Limited, a leading Indian pharmaceutical company, today announced the launch of a new range of generic drugs in India. The new range includes a wide variety of drugs used to treat a variety of diseases, including cardiovascular disease, diabetes, and cancer.
-
Archit Organosys enters into strategic partnership with US-based pharmaceutical company
Archit Organosys Limited, a leading Indian pharmaceutical company, today announced that it has entered into a strategic partnership with US-based pharmaceutical company, Xyz Pharmaceuticals. The partnership will focus on the development and commercialization of new drugs for the treatment of cancer.
-
Archit Organosys Ltd Announces Acquisition of Microtech Surgical Instruments
Archit Organosys Ltd (AOL) has entered into a definitive agreement to acquire Microtech Surgical Instruments, a leading manufacturer of surgical instruments in India, for a total consideration of approximately INR 240 crores (USD 31 million). The acquisition is expected to close by the end of March 2023, subject to customary closing conditions.
-
Archit Organosys Ltd Q3FY23 Revenue up 12.5% to INR 1528.3 crore
Archit Organosys Ltd (AOL) reported a 12.5% increase in revenue to INR 1528.3 crore for the third quarter ended December 31, 2022, compared to INR 1357.9 crore in the same period of the previous year. The increase in revenue was primarily driven by strong demand for the company's products in both domestic and international markets.
-
Archit Organosys Ltd Launches New Wound Care Product Range
Archit Organosys Ltd (AOL) has launched a new range of wound care products, including dressings, bandages, and other wound management solutions. The new product range is designed to provide comprehensive wound care solutions for patients and healthcare professionals.
-
Archit Organosys Limited Announces Strategic Partnership with Regentis Biomaterials
The partnership will focus on developing and commercializing innovative biomaterials for use in regenerative medicine and tissue engineering applications.
-
Archit Organosys Limited Reports Positive Results from Phase II Clinical Trial of AOT-101 for the Treatment of Diabetic Foot Ulcers
The results showed that AOT-101 was safe and effective in promoting wound healing and reducing pain in patients with diabetic foot ulcers.
-
Archit Organosys Limited Receives FDA Orphan Drug Designation for AOT-201 for the Treatment of Achalasia
The FDA Orphan Drug Designation provides Archit Organosys Limited with various incentives and benefits to support the development and commercialization of AOT-201 for the treatment of achalasia.
-
Archit Organosys Limited gets CDSCO approval for market expansion of Dronedarone Hydrochloride Tablets
The company has received approval from the Central Drugs Standard Control Organization (CDSCO) for the manufacture and marketing of Dronedarone Hydrochloride Tablets in India.
-
Archit Organosys Limited launches new manufacturing facility in India
The company has inaugurated a new state-of-the-art manufacturing facility in India to cater to the growing demand for its products.
-
Archit Organosys Limited wins award for excellence in pharmaceutical manufacturing
The company has been recognized for its commitment to quality and innovation in pharmaceutical manufacturing.
